SCHEMBL1196065

SCHEMBL1196065

CC(C)(C)O[C@H](C(=O)O)[C@H](OC(C)(C)C)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
ALDH1A1 P00352 4/20 0.35
MAPT P10636 1/20 0.35
PTGS1 P23219 1/20 0.35
TP53 P04637 2/20 0.33
TSHR P16473 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
KMT2A Q03164 1/20 0.32
PGD P52209 1/20 0.32
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6675517 1.00 SLC1A3 (0.39) SLC1A3SLC1A2SLC1A1ALDH1A1MAPT
SCHEMBL1195466 1.00 SLC1A3 (0.39) SLC1A3SLC1A2SLC1A1ALDH1A1MAPT
SCHEMBL17245264 0.87 MMP1 (0.43) SLC1A3SLC1A2SLC1A1ALDH1A1MAPT
SCHEMBL10417536 0.87 MMP1 (0.43) SLC1A3SLC1A2SLC1A1ALDH1A1MAPT
SCHEMBL17245265 0.87 MMP1 (0.43) SLC1A3SLC1A2SLC1A1ALDH1A1MAPT
SCHEMBL9353746 0.86 TSHR (0.37) SLC1A3SLC1A2SLC1A1TP53TSHR
SCHEMBL24067986 0.83 ALDH1A1 (0.38) SLC1A3SLC1A2SLC1A1ALDH1A1TSHR
SCHEMBL27868667 0.78
SCHEMBL13484732 0.77 ALDH1A1 (0.35) ALDH1A1MAPTPTGS1TP53TSHR
SCHEMBL17416331 0.76 ADH1B (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759583-B2 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation TEVA SANTE (FR) 2014-06-24 US disclosed
US-20130066111-A1 Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation CEPHALON FRANCE (FR) 2013-03-14 US disclosed
US-8318979-B2 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation CEPHALON FRANCE (FR) 2012-11-27 US disclosed
EP-1863760-B1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2012-10-03 EP disclosed
US-8183294-B2 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation Cephelon France (FR) 2012-05-22 US disclosed
US-20120123161-A1 Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation CEPHALON FRANCE (FR) 2012-05-17 US disclosed
US-20110098505-A1 Process for Enantioselective Synthesis of Single Enantiomers of Thio-Substituted Arylmethanesulfinyl Derivatives by Asymmetric Oxidation CEPHALON FRANCE (FR) 2011-04-28 US disclosed
US-7915449-B2 Contacting the corresponding sulfur compound with complex, bas and oxidizer; oxidation; isolation CEPHALON FRANCE (FR) 2011-03-29 US disclosed
US-7893111-B2 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation CEPHALON FRANCE (FR) 2011-02-22 US disclosed
CN-101977909-A Dexlansoprazole process and polymorphs REDDYS LAB LTD DR 2011-02-16 CN disclosed
US-7317126-B2 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation CEPHALON FRANCE (FR) 2008-01-08 US disclosed
EP-1863760-A1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2007-12-12 EP disclosed
EP-1663963-B1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2007-06-27 EP disclosed
WO-2006097814-A1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2006-09-21 WO disclosed
EP-1702915-A1 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation CEPHALON FRANCE (FR) 2006-09-20 EP disclosed
US-20060205706-A1 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation CEPHALON FRANCE (FR) 2006-09-14 US disclosed
EP-1663963-A1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2006-06-07 EP disclosed
US-20050222257-A1 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation CEPHALON, INC. (US) 2005-10-06 US disclosed
US-20050080256-A1 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation TEVA SANTE (FR) 2005-04-14 US disclosed
WO-2005028428-A1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION CEPHALON FRANCE (FR) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098505-A1 Process for Enantioselective Synthesis of Single Enantiomers of Thio-Substituted Arylmethanesulfinyl Derivatives by Asymmetric Oxidation SULT1A1, TST, SULT2A1 SLC1A3 1960/4885SLC1A2 1169/4885SLC1A1 1402/4885
US-20120123161-A1 Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation CYP2F1, SULT1A1, SULT2A1 SLC1A3 1079/4885SLC1A2 497/4885SLC1A1 756/4885
US-20130066111-A1 Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation CYP2F1, SULT1A1, SULT2A1 SLC1A3 1079/4885SLC1A2 497/4885SLC1A1 756/4885
US-20050222257-A1 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation CYP2F1, SULT1A1, SULT2A1 SLC1A3 1079/4885SLC1A2 497/4885SLC1A1 756/4885
US-20060205706-A1 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation SULT1A1, TST, SULT2A1 SLC1A3 1960/4885SLC1A2 1169/4885SLC1A1 1402/4885
US-20050080256-A1 Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation MAOA, CYP2F1, MAOB SLC1A3 1115/4885SLC1A2 493/4885SLC1A1 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.